sur Partners Group (isin : CH0024608827)
Partners Group Exits Initial Investment in PCI Pharma Services
Partners Group has announced its exit from its initial investment in PCI Pharma Services, reaping significant returns for its clients. Since the acquisition in 2016, Partners Group's investments have transformed PCI from a regional packaging entity into a global contract manufacturing and development organization (CDMO).
A consortium, led by Bain Capital and Kohlberg & Company, will acquire a majority stake, while Partners Group will retain a minority stake to facilitate further growth. This strategy focuses on enhancing PCI's capabilities in drug development and manufacturing.
The investment aligns with increasing global pharmaceutical trends. Partners Group has played a key role in expanding PCI's services, which now span advanced drug delivery and biologics production, among others. Ropes & Gray LLP advised on this transaction.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Partners Group